MedTrace Logo

Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism

NCT02812888 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2016-07-06

No results posted yet for this study

Summary

Clustering of various metabolic parameters including abdominal obesity, hyperglycaemia, low high-density lipoprotein cholesterol, elevated triglycerides and hypertension have been used worldwide as metabolic syndrome to predict cardiometabolic risk. Thyroid dysfunction impacts on various levels of these components.

Recent evidence from HepG2 cells indicates that betatrophin, also known as TD26/RIFL/lipasin/ANGPTL8/C19orf80, a secreted protein that regulates glucose, lipid metabolism, and energy homeostasis, is induced by T3. However, the role of betatrophin in hyperthyroid patients is unknown.

The objective was to study serum betatrophin levels in hyperthyroid patients and the association of serum betatrophin levels with hyperthyroidism.

Conditions

  • Hyperthyroidism

Interventions

DRUG

thionamide treatment for 3 months

Hyperthyroid patients would received thionamide treatment (methimazole, propylthiouracil, or propranolol) for 3 months, and euthyroidism would be obtained.

Sponsors & Collaborators

  • Hu Hao

    lead OTHER

Principal Investigators

  • Wang Zhaoling, BD · The First People's Hospital of Xuzhou

  • Hu Hao, MD · The First People's Hospital of Xuzhou

  • Gao Zhaohua, MD · The First People's Hospital of Xuzhou

  • Zhou Tingting, MD · The First People's Hospital of Xuzhou

  • Yin Wenwen, MD · The First People's Hospital of Xuzhou

  • Cai Ruonan, MD · The First People's Hospital of Xuzhou

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-03-31
Completion
2017-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02812888 on ClinicalTrials.gov